Preclinical Alzheimer Disease-Early Diagnosis or Overdiagnosis?

Kenneth M Langa^{1

2

3

4

5}, James F Burke^{3

5

6}

Affiliations

¹ Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor.
² Institute for Social Research, University of Michigan, Ann Arbor.
³ Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
⁴ Institute of Gerontology, University of Michigan, Ann Arbor.
⁵ Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.
⁶ Department of Neurology, University of Michigan, Ann Arbor.

Kenneth M Langa et al. JAMA Intern Med. 2019.

. 2019 Sep 1;179(9):1161-1162.

doi: 10.1001/jamainternmed.2019.2629.

Kenneth M Langa^{1

2

3

4

5}, James F Burke^{3

5

6}

¹ Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor.
² Institute for Social Research, University of Michigan, Ann Arbor.
³ Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
⁴ Institute of Gerontology, University of Michigan, Ann Arbor.
⁵ Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.
⁶ Department of Neurology, University of Michigan, Ann Arbor.

No abstract available

Comment in

Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease.
Rabinovici GD, Carrillo MC. Rabinovici GD, et al. JAMA Intern Med. 2019 Dec 1;179(12):1736-1737. doi: 10.1001/jamainternmed.2019.5114. JAMA Intern Med. 2019. PMID: 31790526 No abstract available.
Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease-Reply.
Burke JF, Langa KM. Burke JF, et al. JAMA Intern Med. 2019 Dec 1;179(12):1737. doi: 10.1001/jamainternmed.2019.5078. JAMA Intern Med. 2019. PMID: 31790532 No abstract available.